To confirm the number of patients who were on Clopidogrel are taking Proton Pump Inhibitors.
Numerous studies examined the clinical outcomes of patients taking clopidogrel and suggested that a significant interaction occurs between clopidogrel and PPIs, making clopidogrel less effective One possible explanation for this observation is that some PPIs prevent the conversion of clopidogrel into its biologically active form in the body
It reduces the effectiveness of clopidogrel and increasing the risk of heart attack or other conditions involving harmful clotting (e.g. strokes).
The EU Committee for Medicinal Products for Human Use (CHMP) has stated that the concomitant use of a proton pump inhibitor (PPI) with clopidogrel is not recommended unless considered essential.
The patients were chosen from the computer records who have been requesting repeat prescriptions of clopidogrel for the last 6 months Medical records from this group of patients were checked manually if they were on PPI’s.
62 patients were identified who were on Clopidogrel Among these patients, 28 were also on PPI’s. The medical records for these patients were highlighted with the information about interaction between clopidogrel and PPI’s.
The interaction between clopidogrel and PPI’S to be discussed with the patient in the next appointment and PPI’s changed to appropriate drug depending on patients needs. A re-audit need to be done to see if the action has been implemented in 6 months time.